Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Long-term follow-up of recovered MPN patients with COVID-19

  • Barbui, Tiziano
  • Andrade-Campos, Marcio
  • Bellosillo Paricio, Beatriz
  • Rambaldi, Alessandro
The study was supported by a research grant by the COVID “3×1 project”, BREMBO S.p.A., Bergamo, Italy (TB) and by AIRC 5×1000 call “Metastatic disease: the key unmet need in oncology” to MYNERVA project, #21267 (MYeloid NEoplasms Research Venture AIRC). A detailed description of the MYNERVA project is available at https://progettomynerva.it (AMV, PG). The study was also supported by HARMONY PLUS, which is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

  • Barbui, Tiziano
  • Andrade-Campos, Marcio
  • Vannucchi, Alessandro Maria
In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in the pre-COVID last follow-up.This decline was remarkably higher in ET (-23.3%, p < 0.0001) than in PV (-16.4%, p = 0.1730) and was associated with higher mortality rate (p = 0.0010) for pneumonia. The effects of possible predictors of thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a multivariate model. Independent risk factors were transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs., The study was also supported by HARMONY PLUS, which is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public–private initiative aiming to speed up the development of better and safer medicines for patients. The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Breakthrough infections in MPN-COVID vaccinated patients

  • Barbui, Tiziano
  • Andrade-Campos, Marcio
  • Vannucchi, Alessandro Maria
The study was supported by a research grant by the COVID “3 × 1 project”, BREMBO S.p.A., Bergamo, Italy (T.B.) and by AIRC 5 × 1000 call “Metastatic disease: the key unmet need in oncology” to MYNERVA project, #21267 (MYeloid NEoplasms Research Venture AIRC). A detailed description of the MYNERVA project is available at https://progettomynerva.it (A.M.V., P.G.). The study was also supported by HARMONY PLUS, which is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public–private initiative aiming to speed up the development of better and safer medicines for patients. The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

  • Barbui, Tiziano
  • Stefano, Valerio De
  • Álvarez Larrán, Alberto
  • Iurlo, Alessandra
  • Masciulli, Arianna
  • Carobbio, Alessandra
  • Ghirardi, Arianna
  • Ferrari, Alberto
  • Cancelli, Valeria
  • Elli, Elena Maria
  • Andrade Campos, Marcio Miguel
  • Gasior Kabat, Mercedes
  • Kiladjian, Jean-Jacques
  • Palandri, Francesca
  • Benevolo, Giulia
  • Garcia Gutierrez, Valentin
  • Fox, Maria Laura
  • Foncillas, Maria Angeles
  • Morcillo, Carmen Montoya
  • Rumi, Elisa
  • Osorio, Santiago
  • Papadopoulos, Petros
  • Bonifacio, Massimiliano
  • Quiroz Cervantes, Keina Susana
  • Serrano, Miguel Sagues
  • Carreño Tarragona, Gonzalo
  • Sobas, Marta Anna
  • Lunghi, Francesca
  • Patriarca, Andrea
  • Elorza, Begoña Navas
  • Angona, Anna
  • Mazo, Elena Magro
  • Koschmieder, Steffen
  • Carli, Giuseppe
  • Cuevas, Beatriz
  • Hernandez Boluda, Juan Carlos
  • Abadia, Emma Lopez
  • Xicoy Cirici, Blanca
  • Guglielmelli, Paola
  • Garrote i Ordeig, Marta
  • Cattaneo, Daniele
  • Daffini, Rosa
  • Cavalca, Fabrizio
  • Bellosillo, Beatriz
  • Benajiba, Lina
  • Curto Garcia, Natalia
  • Bellini, Marta
  • Betti, Silvia
  • Harrison, Claire
  • Rambaldi, Alessandro
  • Vannucchi, Alessandro Maria
In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in the pre-COVID last follow-up.This decline was remarkably higher in ET (-23.3%, p < 0.0001) than in PV (-16.4%, p = 0.1730) and was associated with higher mortality rate (p = 0.0010) for pneumonia. The effects of possible predictors of thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a multivariate model. Independent risk factors were transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

  • Hernández-Sánchez, Alberto
  • González, Teresa
  • Sobas, Marta
  • Sträng, Eric
  • Castellani, Gastone
  • Abáigar, María
  • Valk, Peter J. M.
  • Villaverde-Ramiro, Ángela
  • Benner, Axel
  • Metzeler, Klaus H.
  • Azibeiro, Raúl
  • Tettero, Jesse M.
  • Martínez-López, Joaquín
  • Pratcorona, Marta
  • Martínez Elicegui, Javier
  • Mills, Ken I.
  • Thiede, Christian
  • Sanz, Guillermo
  • Döhner, Konstanze
  • Heuser, Michael
  • Haferlach, Torsten
  • Turki, Amin T.
  • Reinhardt, Dirk
  • Schulze-Rath, Renate
  • Barbus, Martje
  • Hernández, Jesús M.
  • Huntly, Brian J. P.
  • Ossenkoppele, Gert
  • Döhner, Hartmut
  • Bullinger, Lars
Balanced rearrangements involving the KMT2A gene (KMT2Ar) are recurrent genetic abnormalities in acute myeloid leukemia (AML), but there is lack of consensus regarding the prognostic impact of different fusion partners. Moreover, prognostic implications of gene mutations co-occurring with KMT2Ar are not established. From the HARMONY AML database 205 KMT2Ar adult patients were selected, 185 of whom had mutational information by a panel-based next-generation sequencing analysis. Overall survival (OS) was similar across the different translocations, including t(9;11)(p21.3;q23.3)/KMT2A::MLLT3 (p = 0.756). However, independent prognostic factors for OS in intensively treated patients were age >60 years (HR 2.1, p = 0.001), secondary AML (HR 2.2, p = 0.043), DNMT3A-mut (HR 2.1, p = 0.047) and KRAS-mut (HR 2.0, p = 0.005). In the subset of patients with de novo AML < 60 years, KRAS and TP53 were the prognostically most relevant mutated genes, as patients with a mutation of any of those two genes had a lower complete remission rate (50% vs 86%, p < 0.001) and inferior OS (median 7 vs 30 months, p < 0.001). Allogeneic hematopoietic stem cell transplantation in first complete remission was able to improve OS (p = 0.003). Our study highlights the importance of the mutational patterns in adult KMT2Ar AML and provides new insights into more accurate prognostic stratification of these patients., Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). This study presents results from the AML workgroup in HARMONY. AHS is supported by Contrato Río Hortega CM23/00101 (ISCIII). ATT received additional support by the Deutsche Forschungsgemeinschaft (DFG) grant FU 356/12-1 (ATT). Open Access funding enabled and organized by Projekt DEAL., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform

  • Mosquera Orgueira, Adrián
  • González Pérez, Marta Sonia
  • D'Agostino, Mattia
  • Cairns, David A.
  • Larocca, Alessandra
  • Lahuerta, Juan José
  • Wester, R.
  • Bertsch, Uta
  • Zamagni, Elena
  • Pérez Míguez, Carlos
  • Rojas Martínez, Javier Alberto
  • Mai, Elias K.
  • Crucitti, Davide
  • Salwender, Hans
  • Dall’Olio, Daniele
  • Castellani, Gastone
  • Piñeiro, Manuel
  • Bringhen, Sara
  • Zweegman, Sonja
  • Cavo, Michele
  • Iqbal, Sofía
  • Hernández, Jesús M.
  • Bruno, Benedetto
  • Cook, Gordon
  • Kaiser, Martin F.
  • Goldschmidt, Hartmut
  • Donk, Niels W. C. J. van de
  • Jackson, Graham
  • San Miguel, Jesús F.
  • Boccadoro, Mario
  • Mateos, Maria Victoria
  • Sonneveld, Pieter
Traditional risk stratification in multiple myeloma (MM) relies on clinical and cytogenetic parameters but has limited predictive accuracy. Machine learning (ML) offers a novel approach by leveraging large datasets and complex variable interactions. This study aimed to develop and validate novel ML-driven prognostic scores for newly diagnosed MM (NDMM), with the goal of improving upon existing ones. To this end, we analyzed data from the EMN–HARMONY MM cohort, comprising 14,345 patients, including 10,843 NDMM patients enrolled across 16 clinical trials. Three ML models were developed: (1) a comprehensive model incorporating 20 variables, (2) a reduced model including six key variables (age, hemoglobin, β2-microglobulin, albumin, 1q gain, and 17p deletion), and (3) a cytogenetics-free model. All models were internally validated using out-of-bag cross-validation and externally validated with data from the Myeloma XI trial. Model performance was evaluated using the concordance index (C-index) and time-dependent area under the receiver operating characteristic curve (ROC-AUC). The comprehensive model achieved C-index values of 0.666 (training) and 0.667 (test) for overall survival (OS) and 0.620/0.627 for progression-free survival (PFS). The reduced model maintained accuracy (OS: 0.658/0.657; PFS: 0.608/0.614). The cytogenetics-free model showed C-index values of 0.636/0.643 for OS and 0.600/0.610 for PFS. Incorporating treatment type and best response to first-line treatment further improved performance. The new prognostic models improved over the International Staging System (ISS), Revised International Staging System (R-ISS), and Second Revision of the International Staging System (R2-ISS) and were reproducible in real-world and relapsed/refractory MM, including daratumumab-treated patients. This ML-based risk stratification strategy provides individualized risk predictions, surpassing traditional group-based methods and demonstrating broad applicability across patient subgroups., This work was supported by the HARMONY and HARMONY PLUS projects (IMI2 Joint Undertaking under grant agreements No. 116026 and No. 945406), which receive funding from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

  • Barbui, Tiziano
  • Andrade-Campos, Marcio
  • Vannucchi, Alessandro Maria
In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in the pre-COVID last follow-up.This decline was remarkably higher in ET (-23.3%, p < 0.0001) than in PV (-16.4%, p = 0.1730) and was associated with higher mortality rate (p = 0.0010) for pneumonia. The effects of possible predictors of thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a multivariate model. Independent risk factors were transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs., The study was also supported by HARMONY PLUS, which is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public–private initiative aiming to speed up the development of better and safer medicines for patients. The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Breakthrough infections in MPN-COVID vaccinated patients

  • Barbui, Tiziano
  • Andrade-Campos, Marcio
  • Vannucchi, Alessandro Maria
The study was supported by a research grant by the COVID “3 × 1 project”, BREMBO S.p.A., Bergamo, Italy (T.B.) and by AIRC 5 × 1000 call “Metastatic disease: the key unmet need in oncology” to MYNERVA project, #21267 (MYeloid NEoplasms Research Venture AIRC). A detailed description of the MYNERVA project is available at https://progettomynerva.it (A.M.V., P.G.). The study was also supported by HARMONY PLUS, which is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public–private initiative aiming to speed up the development of better and safer medicines for patients. The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

  • Barbui, Tiziano
  • Stefano, Valerio De
  • Álvarez Larrán, Alberto
  • Iurlo, Alessandra
  • Masciulli, Arianna
  • Carobbio, Alessandra
  • Ghirardi, Arianna
  • Ferrari, Alberto
  • Cancelli, Valeria
  • Elli, Elena Maria
  • Andrade Campos, Marcio Miguel
  • Gasior Kabat, Mercedes
  • Kiladjian, Jean-Jacques
  • Palandri, Francesca
  • Benevolo, Giulia
  • Garcia Gutierrez, Valentin
  • Fox, Maria Laura
  • Foncillas, Maria Angeles
  • Morcillo, Carmen Montoya
  • Rumi, Elisa
  • Osorio, Santiago
  • Papadopoulos, Petros
  • Bonifacio, Massimiliano
  • Quiroz Cervantes, Keina Susana
  • Serrano, Miguel Sagues
  • Carreño Tarragona, Gonzalo
  • Sobas, Marta Anna
  • Lunghi, Francesca
  • Patriarca, Andrea
  • Elorza, Begoña Navas
  • Angona, Anna
  • Mazo, Elena Magro
  • Koschmieder, Steffen
  • Carli, Giuseppe
  • Cuevas, Beatriz
  • Hernandez Boluda, Juan Carlos
  • Abadia, Emma Lopez
  • Xicoy Cirici, Blanca
  • Guglielmelli, Paola
  • Garrote i Ordeig, Marta
  • Cattaneo, Daniele
  • Daffini, Rosa
  • Cavalca, Fabrizio
  • Bellosillo, Beatriz
  • Benajiba, Lina
  • Curto Garcia, Natalia
  • Bellini, Marta
  • Betti, Silvia
  • Harrison, Claire
  • Rambaldi, Alessandro
  • Vannucchi, Alessandro Maria
In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up. Of note, 8 of 12 VTE were seen in ET. Interestingly, at COVID-19 diagnosis, MPN patients had significantly lower platelet count (p < 0.0001) than in the pre-COVID last follow-up.This decline was remarkably higher in ET (-23.3%, p < 0.0001) than in PV (-16.4%, p = 0.1730) and was associated with higher mortality rate (p = 0.0010) for pneumonia. The effects of possible predictors of thrombosis, selected from those clinically relevant and statistically significant in univariate analysis, were examined in a multivariate model. Independent risk factors were transfer to ICU (SHR = 3.73, p = 0.029), neutrophil/lymphocyte ratio (SHR = 1.1, p = 0.001) and ET phenotype (SHR = 4.37, p = 0.006). The enhanced susceptibility to ET-associated VTE and the associated higher mortality for pneumonia may recognize a common biological plausibility and deserve to be delved to tailor new antithrombotic regimens including antiplatelet drugs.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Long-term follow-up of recovered MPN patients with COVID-19

  • Barbui, Tiziano
  • Andrade-Campos, Marcio
  • Bellosillo Paricio, Beatriz
  • Rambaldi, Alessandro
The study was supported by a research grant by the COVID “3×1 project”, BREMBO S.p.A., Bergamo, Italy (TB) and by AIRC 5×1000 call “Metastatic disease: the key unmet need in oncology” to MYNERVA project, #21267 (MYeloid NEoplasms Research Venture AIRC). A detailed description of the MYNERVA project is available at https://progettomynerva.it (AMV, PG). The study was also supported by HARMONY PLUS, which is funded through the Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. The HARMONY Alliance has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long-term follow-up of recovered MPN patients with COVID-19

  • Barbui, Tiziano|||0000-0003-2747-6327
  • Iurlo, Alessandra|||0000-0002-4401-0812
  • Masciulli, Arianna
  • Carobbio, Alessandra|||0000-0001-9664-7084
  • Ghirardi, Arianna
  • Rossi, Giuseppe
  • Harrison, Claire
  • Álvarez Larrán, Alberto|||0000-0001-6387-4619
  • Elli, Elena Maria
  • Kiladjian, Jean-Jaques
  • Gasior Kabat, Mercedes
  • Marin Sanchez, Alberto
  • Palandri, Francesca|||0000-0001-8367-5668
  • Andrade-Campos, Marcio Miguel|||0000-0003-1637-7112
  • Vannucchi, Alessandro Maria
  • Carreño-Tarragona, Gonzalo|||0000-0002-9570-5542
  • Papadopoulos, Petros
  • Quiroz Cervantes, Keina|||0000-0001-8553-3524
  • Foncillas, Maria Angeles|||0000-0002-3511-0504
  • Fox, Maria Laura|||0000-0002-0062-6607
  • Sagues Serrano, Miguel
  • Rumi, Elisa|||0000-0002-7572-9504
  • Osorio, Santiago
  • Benevolo, Giulia
  • Patriarca, Andrea|||0000-0003-4415-2906
  • Navas Elorza, Begoña
  • García Gutiérrez, Valentín|||0000-0003-4752-0815
  • Magro Mazo, Elena
  • Lunghi, Francesca
  • Bonifacio, Massimiliano|||0000-0003-0716-1686
  • De Stefano, Valerio|||0000-0002-5178-5827
  • Hernandez-Boluda, Juan Carlos|||0000-0002-4289-3113
  • Lopez Abadia, Emma
  • Angona, Anna|||0000-0002-0965-9501
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Ruggeri, Marco
  • Koschmieder, Steffen|||0000-0002-1011-8171
  • Sobas, Marta Anna
  • Cuevas, Beatriz|||0000-0001-7555-3361
  • Cattaneo, Daniele|||0000-0002-7571-023X
  • Daffini, Rosa
  • Bellini, Marta
  • Curto-Garcia, Natalia
  • Garrote, Marta
  • Cavalca, Fabrizio
  • Benajiba, Lina
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Guglielmelli, Paola|||0000-0003-1809-284X
  • Borsani, Oscar|||0000-0001-7805-7806
  • Betti, Silvia
  • Salmoiraghi, Silvia
  • Rambaldi, Alessandro|||0000-0002-3739-7502